Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206043) titled 'Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
Primary Sponsor: R-Pharm International, LLC
Condition:
Healthy
Intervention:
Biological: RPH-104 80 mg
Biological: RPH-104 160 mg
Biological: RPH-104 320 mg
Biological: RPH-104 320 mg
Biological: RPH-104 80 mg
Biological: RPH-104 80 mg
Recruitment Status: Not recruiting...